Implementation of an Opioid Use Disorder (OUD) Machine-Learning Phenotype in Real-Time for the ADAPT Project

Real-Time Implementation of OUD Machine-Learning Phenotype

Authors: Huan Li, PhD [*, 1, 2]; Mark Iscoe, MD, MHS [1,2]; John Lutz [1]; Carolina Diniz Hopper, MD [1]; Sabrina Fried, MD [1]; Josue Minaya, MD [1]; Caroline Raymond King, MD, PhD [1]; Olga Reykhart, MD [1]; Hyung Paek, MD, MSEE [2,3]; Daniella Meeker, PhD [2]; Edward R. Melnick, MD, MHS [¶, 1,2,3]; R.Andrew Taylor, MD, MHS [¶, 2,4]

Academic affiliation for all authors

[1] Department of Emergency Medicine, Yale University School of Medicine, New Haven, CT, USA

[2] Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, CT, USA

[3] Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

[4] Department of Emergency Medicine, University of Virginia, Charlottesville, VA, USA

*** Corresponding Author**

Huan Li, PhD

Department of Emergency Medicine

464 Congress Ave # 260

New Haven, CT 06519

Telephone (518) 833-4657

e-mail: huan.li@yale.edu

¶ E.R.M. and R.A.T. contributed equally to this work and should be considered co-last authors.

Word count: 4060

Author Contributions

H.L.: *Conceptualization, Methodology, Data curation, Formal analysis, Software, Visualization, Writing – original draft*; M.I.: *Conceptualization, Validation, Investigation, Writing – review & editing*; J.L.: *Data curation, Software, Technical support*; C.D.H.: *Writing – original draft (Introduction), Writing – review & editing*; S.F., J.M., C.R.K., O.R.: *Investigation (Chart review), Validation*; H.P.: *Data curation, Resources*; D.M.: *Methodology, Conceptualization, Writing – review & editing*; E.R.M., R.A.T.: *Supervision, Conceptualization, Project administration, Writing – review & editing*. All authors reviewed and approved the final version of the manuscript.

Funding

Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R33DA059884. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abstract

Objective: Develop and deploy a real-time, EHR-integrated machine learning phenotype to identify emergency department (ED) patients with opioid use disorder (OUD) for prospective clinical trial screening and buprenorphine initiation.

Materials and Methods: We conducted a multi-phase study across three EDs in a single United States health system from 2014 to 2025. Using visit-level data available at or before triage, we trained a random-forest classifier to estimate OUD risk and embedded scoring in the EHR to trigger point-of-care alerts for trial eligibility review. A computable silver-standard label supported retrospective development; a clinician gold-standard reference was established via structured, DSM-5–aligned chart review. Performance was summarized with ROC-/PR-AUC, calibration, and threshold-based classification metrics; prospective validation used a stratified random sample of flagged and unflagged encounters.

Results: Retrospective discrimination compared to the silver standard was high (ROC-AUC 0.99, 95% CI 0.98-0.99; PR-AUC 0.92, 95% CI 0.90-0.94), and calibration plots informed operating-point selection for real-time use. In prospective gold-standard validation (n=218), the positive predictive value was 98.28%, and the negative predictive value was 95.68% at the prespecified threshold.

Discussion and Conclusion: An EHR-embedded, machine-learning phenotype can accurately and feasibly identify ED patients with OUD in real time, streamlining clinical trial enrollment and treatment initiation. Ongoing work will report operational metrics (e.g., alert volume and latency), monitor performance drift and equity across subgroups, and evaluate downstream clinical and trial outcomes.

Author Summary

In this study, we wanted to find a better way to identify people visiting the emergency department who may be living with opioid use problems. These patients are often hard to recognize quickly, even though timely support, including offering effective medications, can greatly improve their health and safety. Traditional approaches rely heavily on clinicians noticing certain patterns in real time, which can be challenging during busy emergency care. To address this gap, we examined over a decade of information from a large health system and developed a clinical decision support tool that reviews routine information collected at the start of an emergency visit. The tool gives clinicians a simple, real-time signal when a patient may benefit from additional evaluation or treatment. Our early experience shows that this approach can help teams identify patients more consistently and connect them to care more quickly. We hope this work will make it easier for hospitals to support people affected by opioid use and to run clinical studies that improve future treatment options.

Introduction

The opioid crisis continues to evolve as one of the most urgent and complex public health emergencies in the United States. The number of overdose deaths attributed to fentanyl analogs rose by 540% from 2013 to 2016, and in 2022 alone, more than 109,000 drug overdose deaths occurred nationwide, and nearly 70% of these involved opioids.[1,2] Emergency departments (EDs) and frontline services, including emergency medical services, are frequently the first or only point of healthcare contact for individuals with opioid use disorder (OUD) at high risk of overdose. In 2018, opioids were involved in roughly one-quarter of all drug-related ED visits across the United States, and recent studies indicate that the COVID-19 pandemic further intensified opioid-related ED utilization.[3,4] Thus, EDs are critical access points for detection and intervention for OUD.[3,4]

Buprenorphine is a medication for opioid use disorder (MOUD) with evidence for both its effectiveness at reducing illicit opioid use and opioid-related mortality and the viability of initiating use in the ED setting.[5–8] Despite the availability of an effective treatment and intervention, only a small subset of eligible patients, approximately 6-8%, receive buprenorphine in the ED,[9] with limitations in its prescription and uptake related to prescribers'[5–8] lack of experience with the medication, concerns for impact on workflow and drug diversion, and persisting stigma.[10,11] Our group's prior initiative, the EMBED trial, attempted to mitigate some of these gaps by developing a clinical decision support (CDS) tool for buprenorphine initiation in the ED, but was ineffective at increasing patient-level rates of buprenorphine initiation.[12] In the ongoing ADAPT trial, we aim to build upon the work in EMBED and improve intervention effectiveness through a Multiphase Optimization Strategy Trial.[13] A crucial step toward

106 enhancing the adoption of ED-initiated buprenorphine is the accurate identification of potentially
107 eligible OUD patients. Automated detection of OUD within electronic health records could
108 enable earlier intervention, facilitate clinical trial enrollment, and strengthen linkage to treatment.
109 Patient phenotyping through machine learning offers a practical solution to real-time patient
110 identification.
111
112 Previous studies have used machine learning to stratify individuals according to their risk of
113 developing or currently suffering from OUD and opioid overdose based on electronic health
114 record (EHR) data. While several models have shown a strong predictive performance in
115 retrospective settings,[14–16] a lack of workflow integration has often limited their real-world
116 application. In parallel, Chartash et al. in the EMBED trial[17] and Taylor et al.[18] have
117 demonstrated that phenotypes using structured and nuanced data from patient charts can
118 accurately identify patients with opioid-related disorders presenting to the ED. However, these
119 phenotypes were retrospective and lacked real-time identification of eligible patients at the point
120 of care.
121
122 To address these gaps, we developed and implemented a real-time, EHR-integrated, machine
123 learning OUD phenotype to identify ED patients for prospective clinical-trial screening and to
124 support ED-initiated buprenorphine as part of a nationally disseminated, multicomponent clinical
125 decision support (CDS) program.[13] We hypothesized that a calibrated, real-time phenotype,
126 embedded within routine ED workflow, would achieve high sensitivity with acceptable

specificity at a prespecified threshold, thereby enabling timely identification of candidates for treatment and rigorous prospective evaluation.

Results

Participants and Descriptive Data

In the retrospective observation phase of this study, a total of 3,177,664 unique patients met the inclusion criteria, representing all adult patients with ED visits in the health system between 2014 and 2025. Following outcome-based balancing, the training dataset included 17,054 patients, and the test dataset included 4,246 patients. Within the overall population, 1,336,335 (42.05%, **Table 1**) were aged 18-39 years, 972,293 (30.60%) were aged 40-64 years, and 869,016 (27.35%) were 65 years or older. These age group distributions were similarly reflected in both the training and test datasets after balancing. In the overall population, 1,707,449 (53.73%) were female and 1,466,587 (46.15%) were male, with comparable distributions maintained in the training and test datasets. The racial/ethnic composition of the overall population was 59.81% White or Caucasian, 10.21% Black or African American, and 14.42% Hispanic. This composition was also similar in both the training and test datasets after balancing.

Table 1. **Study Population Demographics**

	Overall Population (n = 3,177,664)	**Balanced Training Dataset (n = 17,054)**	**Balanced Testing Dataset (n = 4,246)**
Age group, n (%)			
18-39	1,336,335 (42.05%)	7,127 (41.79%)	1,761 (41.47%)
40-64	972,293 (30.60%)	5,642 (33.08%)	1,408 (33.16%)
65+	869,016 (27.35%)	4,285 (25.13%)	1,077 (25.37%)
Sex, n (%)			
Female	1,707,449 (53.73%)	8,799 (51.59%)	2,200 (52.28%)

Male	1,466,587 (46.15%)	8,246 (48.35%)	2,023 (47.64%)
Other or Unknow	3,628 (0.11%)	9 (0.05%)	3 (0.07%)
Race, n (%)			
White or Caucasian	1,900,669 (59.81%)	10,897 (63.90%)	2,788 (65.66%)
Black or African American	324,332 (10.21%)	1,931 (11.32%)	452 (10.65%)
Asian	109,581 (3.45%)	569 (3.34%)	116 (2.73%)
American Indian or Alaska Native	9,182 (0.29%)	62 (0.36%)	10 (0.24%)
Native Hawaiian or Other Pacific Islander	4,962 (0.16%)	20 (0.12%)	10 (0.24%)
Other or Unknown	828,938 (26.09%)	3,575 (20.96%)	870 (20.49%)
Ethnicity, n (%)			
Non-Hispanic	2,058,420 (64.78%)	12,461 (73.07%)	3,112 (73.29%)
Hispanic or Latino	458,068 (14.42%)	2,758 (16.17%)	682 (16.06%)
Other or Unknown	661,176 (20.81%)	1,835 (10.76%)	452 (10.64%)
PMH, n (%) >=1			
Substance Use Disorder Diagnoses	49,863 (1.57%)	1,536 (9.01%) †	379 (8.93%) †
Mental Diagnoses	107,142 (3.37%)	1,723 (10.10%)	452 (10.65%)
Chronic Illnesses			
Diabetes	324,586 (10.21%)	2,245 (13.16%)	585 (13.78%)
Heart Disease	280,286 (8.82%)	2,023 (11.86%)	526 (12.39%)
Hypertension	773,361 (24.34%)	5,286 (31.00%)	1,335 (31.44%)
Medication			
MOUD*	58,178 (1.83%)	1,336 (7.83%)	375 (8.83%)
Other opioids	817,469 (25.73%)	6,081 (35.66%)	1,547 (36.43%)
Naloxone	264,999 (8.34%)	2,624 (15.39%)	698 (16.44%)

* MOUD stands medication of opioid use disorder and includes methadone, buprenorphine, naltrexone)

† Substance use disorder diagnoses defined after labeling patients with > 250 cumulative OUD codes as positive.

In terms of relevant past medical history (PMH), 1.57% of the overall population had a documented substance use disorder, 3.37% had mental health diagnoses, and among selected chronic illnesses, 10.21% had diabetes, 8.82% had heart disease, and 24.34% had hypertension. Regarding medication use, 1.83% had prescriptions for medications for opioid use disorder

(MOUD: methadone, buprenorphine, or naltrexone), 25.73% for other opioids, and 8.34% for naloxone.

Unlike demographic characteristics, PMH and medication prevalence, by design, differed between the training and test datasets due to the balancing procedure. In the balanced training set, prevalence rates were higher: 9.01% for substance use disorder, 10.10% for mental health diagnoses, 13.16% for diabetes, 11.86% for heart disease, and 31.00% for hypertension. Corresponding rates in the test set were similar: 8.93%, 10.65%, 13.78%, 12.39%, and 31.44%, respectively. MOUD use was 7.83% in training and 8.83% in testing; other opioid use was 35.66% and 36.43%; naloxone med list rates were 15.39% and 16.44%.

Phenotype Model Outcomes

The random forest classifier model predicted the patients with a positive OUD phenotype (based on the sliver standard) with a sensitivity of 0.549, specificity of 0.997, precision of 0.945, NPV of 0.958, FPR of 0.003, FNR of 0.451, accuracy of 0.957, and F1 score of 0.694, when evaluated at the default probability threshold of 0.50. Additional evaluations using alternative probability thresholds are presented in **Table 2**.

169 **Table 2. Performance Metrics of the Predictive Model**

Threshold	Sensitivity (TPR) [95% CI]	Specificity (TNR) [95% CI]	Precision (PPV) [95% CI]	Negative Predictive Value (NPV) [95% CI]	False Positive Rate (FPR) [95% CI]	False Negative Rate (FNR) [95% CI]	Accuracy [95% CI]	F1-Score [95% CI]
0.05	0.995 [0.987, 1.000]	0.761 [0.747, 0.775]	0.290 [0.266, 0.314]	0.999 [0.998, 1.000]	0.239 [0.225, 0.253]	0.005 [0.000, 0.013]	0.782 [0.770, 0.794]	0.449 [0.419, 0.478]
0.1	0.976 [0.960, 0.990]	0.916 [0.907, 0.924]	0.532 [0.497, 0.570]	0.997 [0.996, 0.999]	0.084 [0.076, 0.093]	0.024 [0.010, 0.040]	0.921 [0.913, 0.929]	0.689 [0.658, 0.721]
0.15	0.971 [0.953, 0.987]	0.957 [0.950, 0.963]	0.687 [0.646, 0.727]	0.997 [0.995, 0.999]	0.043 [0.037, 0.050]	0.029 [0.013, 0.047]	0.958 [0.952, 0.964]	0.804 [0.776, 0.833]
0.2	0.939 [0.914, 0.962]	0.972 [0.966, 0.977]	0.766 [0.725, 0.804]	0.994 [0.991, 0.996]	0.028 [0.023, 0.034]	0.061 [0.038, 0.086]	0.969 [0.963, 0.974]	0.844 [0.816, 0.869]
0.25	0.894 [0.859, 0.925]	0.984 . [0.980, 0.988]	0.845 [0.810, 0.880]	0.990 [0.986, 0.993]	0.016 [0.012, 0.020]	0.106 [0.075, 0.141]	0.976 [0.971, 0.980]	0.869 [0.842, 0.892]
0.3	0.818 [0.776, 0.855]	0.989 [0.986, 0.992]	0.878 [0.843, 0.911]	0.982 [0.978, 0.986]	0.011 [0.008, 0.014]	0.182 [0.145, 0.224]	0.974 [0.969, 0.978]	0.847 [0.819, 0.873]
0.35	0.752 [0.710, 0.792]	0.993 [0.990, 0.995]	0.911 [0.878, 0.939]	0.976 [0.972, 0.981]	0.007 [0.005, 0.010]	0.248 [0.208, 0.290]	0.971 [0.967, 0.976]	0.824 [0.793, 0.851]
0.4	0.673 [0.624, 0.718]	0.995 [0.992, 0.997]	0.927 [0.897, 0.957]	0.969 [0.963, 0.974]	0.005 [0.003, 0.008]	0.327 [0.282, 0.376]	0.966 [0.960, 0.972]	0.780 [0.743, 0.813]
0.45	0.599 [0.548, 0.648]	0.996 [0.994, 0.998]	0.942 [0.911, 0.970]	0.962 [0.956, 0.968]	0.004 [0.002, 0.006]	0.401 [0.352, 0.452]	0.961 [0.955, 0.967]	0.732 [0.691, 0.769]
0.5	0.549 [0.502, 0.596]	0.997 [0.995, 0.998]	0.945 [0.914, 0.973]	0.958 [0.951, 0.963]	0.003 [0.002, 0.005]	0.451 [0.404, 0.498]	0.957 [0.951, 0.963]	0.694 [0.654, 0.733]
0.55	0.464 [0.415, 0.516]	0.997 [0.995, 0.998]	0.936 [0.899, 0.970]	0.950 [0.944, 0.957]	0.003 [0.002, 0.005]	0.536 [0.484, 0.585]	0.949 [0.943, 0.956]	0.621 [0.573, 0.667]
0.6	0.425 [0.376, 0.475]	0.998 [0.996, 0.999]	0.953 [0.916, 0.982]	0.947 [0.939, 0.954]	0.002 [0.001, 0.004]	0.575 [0.525, 0.624]	0.947 [0.940, 0.954]	0.588 [0.538, 0.635]
0.65	0.380 [0.334, 0.425]	0.998 [0.996, 0.999]	0.947 [0.908, 0.979]	0.943 [0.936, 0.950]	0.002 [0.001, 0.004]	0.620 [0.575, 0.666]	0.943 [0.935, 0.949]	0.542 [0.493, 0.590]
0.7	0.325 [0.278, 0.369]	0.999 [0.998, 1.000]	0.969 [0.935, 0.993]	0.938 [0.930, 0.945]	0.001 [0.000, 0.002]	0.675 [0.631, 0.722]	0.939 [0.931, 0.945]	0.486 [0.430, 0.536]
0.75	0.251 [0.207, 0.296]	0.999 [0.999, 1.000]	0.979 [0.945, 1.000]	0.932 [0.924, 0.939]	0.001 [0.000, 0.001]	0.749 [0.704, 0.793]	0.933 [0.925, 0.940]	0.399 [0.342, 0.455]

0.8	0.182 [0.144, 0.221]	1.000 [1.000, 1.000]	1.000 [1.000, 1.000]	0.926 [0.918, 0.933]	0.000 [0.000, 0.000]	0.818 [0.779, 0.856]	0.927 [0.919, 0.934]	0.308 [0.252, 0.362]
0.85	0.108 [0.078, 0.142]	1.000 [1.000, 1.000]	1.000 [1.000, 1.000]	0.920 [0.912, 0.928]	0.000 [0.000, 0.000]	0.892 [0.858, 0.922]	0.920 [0.913, 0.928]	0.195 [0.144, 0.248]
0.9	0.018 [0.006, 0.034]	1.000 [1.000, 1.000]	1.000 [1.000, 1.000]	0.912 [0.904, 0.921]	0.000 [0.000, 0.000]	0.982 [0.966, 0.994]	0.912 [0.904, 0.921]	0.036 [0.011, 0.065]
0.95	0.000 [0.000, 0.000]	1.000 [1.000, 1.000]	0.000 [0.000, 0.000]	0.911 [0.902, 0.919]	0.000 [0.000, 0.000]	1.000 [1.000, 1.000]	0.911 [0.902, 0.919]	0.000 [0.000, 0.000]

172 At the default probability threshold of 0.50, the confusion matrix demonstrated 202 true
173 positives, 10 false positives, 3805 true negatives, and 172 false negatives (**Figure 1a**). The ROC
174 curve yielded an AUC of 0.99 (95% CI 0.98-0.99), indicating strong overall discrimination
175 between patients with and without OUD (**Figure 1b**). The precision–recall curve produced an
176 AUC of 0.92 (95%CI 0.90- 0.94), supporting the model's ability to preserve positive predictive
177 value under class imbalance (**Figure 1c**). Finally, the calibration curve demonstrated that
178 predicted probabilities were underestimated across the observed risk spectrum, especially for
179 higher predicted probabilities (**Figure 1d**).

180 **Figure 1. Silver Standard Prediction Model Performance Evaluations:** a) confusion matrix at the default
181 probability threshold of 0.50, b) Receiver operating characteristic (ROC) curve with area under the curve (AUC), c)
182 precision-recall (PR) curve with area under the curve, d) calibration curve comparing predicted versus observed
183 probabilities.

184 The top 25 predictive features, ranked by feature importance, derived from the random forest
185 classifier, are presented in **Figure 2** (full list in **Appendix 1**). At the individual feature level, the
186 most influential predictors of the OUD phenotype were diagnoses related to substance use
187 disorders other than OUD. At the category level, features pertaining to PMH contributed the
188 greatest overall importance, followed by medication-related variables and laboratory results.
189 Notably, the top two of the three individual features belonged to the PMH category.

190 **Figure 2. Feature Importance of Predictors for OUD Phenotype:** Bar size represents the relative importance of
191 each of the top 25 predictors, as estimated by the random forest classifier. Colors indicate feature categories: PMH
192 (blue), medication (orange), labs (green), procedures (red), and other (purple).

193 *Gold Standard Evaluation*

194 In the prospective validation phase of the study, there were 217 patients in the gold standard
195 validation set, including 96 (44.24%, **Table 3**) classified by the model as having OUD and
196 121(55.76%) classified as not having OUD. We initially selected 200 patients for chart review
197 and subsequently added 20 additional cases (for a total of 220) to ensure sufficient sample size
198 after applying exclusion criteria. Three patients were excluded (one younger than 18 years and
199 two who were pregnant), resulting in the final cohort size reported above. Of these patients,
200 42.86% (n = 93) were female and 57.14% (n = 125) were male. The age distribution was as
201 follows: 24.54% (n = 53) were aged 18–39 years, 48.15% (n = 105) were aged 40–64 years, and
202 27.31% (n = 60) were aged 65 years and older. Regarding race and ethnicity, 67.28% (n = 147)
203 of patients identified as White or Caucasian, 22.58% (n = 49) as Black or African American,
204 19.32% (n = 43) as Hispanic or Latino, and 0.46% (n = 1) as Asian. After chart review, 103 were
205 ultimately adjudicated as having OUD and 114 as not having OUD. Cohen's kappa for inter-
206 reviewer agreement was 0.86. Of the 17 cases in which resident reviewers disagreed on patients'
207 OUD status, attending physician adjudicators initially agreed on 13 (76%) and reached a
208 consensus on the remaining 4 cases after discussion. The demographic composition of the
209 validation set was broadly comparable between patients with and without OUD, as determined
210 by gold standard manual chart review. The age distribution differed slightly, with a higher
211 proportion of patients aged 40–64 years in the OUD positive group and a higher proportion aged
212 65 years and older in the OUD negative group.

213 **Table 3. Gold Standard Validation Group Demographics**

	Overall (n = 217)	**OUD Yes (n = 103)**	**OUD No (n = 114)**
Age group, n (%)			

18-39	53 (24.54%)	26 (25.24%)	27 (23.89%)
40-64	104 (48.15%)	60 (58.25%)	44 (38.94%)
65+	59 (27.31%)	17 (16.50%)	42 (37.17%)
Sex, n (%)			
Female	93 (42.86%)	39 (37.86%)	54 (47.37%)
Male	124 (57.14%)	64 (62.14%)	60 (52.63%)
Unknow	0		
Race, n (%)			
White or Caucasian	146 (67.28%)	75 (72.82%)	71 (62.28%)
Black or African American	49 (22.58%)	20 (19.42%)	29 (25.44%)
Asian	1 (0.46%)	0	1 (0.88%)
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other or Unknown	22 (10.14%)	8 (7.77%)	13 (11.40%)
Ethnicity, n (%)			
Non-Hispanic	170 (78.34%)	81 (78.64%)	89 (78.07%)
Hispanic or Latino	43 (19.82%)	21 (20.39)	22 (19.30%)
Unknown	4 (1.84%)	1 (0.97%)	3 (2.63%)

Model performance evaluated against the gold standard OUD labels in the validation set (**Figure 3**), identified 92 true positives (TP), 110 true negatives (TN), 11 false positives (FP), and 5 false

negatives (FN, **Figure 3**). The model yielded a sensitivity of 0.958 (95% CI: 0.898 - 0.984) and a specificity of 0.909 (95% CI: 0.845 - 0.948) with respect to the gold standard.

Figure 3. Gold Standard Validation Outcome Confusion Metrics. The figure presents the distribution of TP, FP, TN, and FN from the validation set. Each cell represents the count of patients correctly or incorrectly classified by the model after chart review based on the gold standard. The model demonstrated high agreement with the gold standard.

Discussion

In this multi-phase study, we developed, implemented, and prospectively validated an EHR-embedded phenotype capable of accurately identifying patients with OUD in real time. By integrating daily inference within existing data infrastructure, we demonstrated that automated phenotyping can transition from retrospective research to prospective clinical application with minimal latency. The model's high predictive performance and operational feasibility highlight its potential to enhance clinical care and clinical trial efficiency for ED patients with OUD.

The phenotype classifier model demonstrated excellent performance in identifying patients with OUD, achieving a high AUC of 0.99 in the silver standard evaluation based on diagnostic codes, and a sensitivity of 0.96 and specificity of 0.91 in the gold-standard validation based on physician adjudication of charts; this performance is substantially higher than values reported in prior studies using EHR-based prediction models for substance use disorders, which have ranged from 0.80 to 0.95 with the majority falling in the 0.85 - 0.90 range.[19,20] The strong performance observed in both retrospective and prospective validation phases highlights the model's robustness and reproducibility. Several factors may have contributed to this strong performance, including the use of a high-quality outcome definition (silver standard), the construction of

239 features from detailed EHR data that captured robust patterns indicative of OUD, and the
240 application of tree-based models, which are well-suited for handling non-linear relationships and
241 complex interactions among clinical features. Additionally, the model's predictions were highly
242 consistent with the gold-standard chart review outcomes, demonstrating strong alignment
243 between algorithmic classification and clinical validation.

244 The pipeline was designed to operate within standard EHR data structures and executed
245 efficiently using distributed computing, demonstrating technical feasibility for real-time
246 integration. Our implementation also differs from prior work by closing the loop operationally—
247 nightly OMOP harmonization, daily inference, and EHR-native rules—yielding ≤ 24-hour
248 latency.[21] These findings suggest that real-time deployment within the EHR environment is both
249 technically feasible and clinically effective, enabling timely identification of patients at risk for
250 OUD who could benefit from appropriate ED intervention and treatment. While the EMBED
251 pragmatic trial demonstrated that CDS alone does not guarantee population-level uptake;[22] the
252 new phenotype presented here could address these challenges by offering a maintainable
253 pathway for automated, real-time screening to support increased patient identification and
254 subsequent treatment. Finally, multi-site rule sets have demonstrated portability across health
255 systems; by grounding our pipeline in standard vocabularies and OMOP, we similarly position
256 the phenotype for reuse and external validation.[17]

257 Prior ED phenotyping efforts have primarily relied on rule-based algorithms anchored to
258 diagnosis codes and a small set of structured signals. While precise, these approaches: 1) under-
259 detect uncoded OUD, and 2) do not allow for detection and intervention during the encounter
260 itself (given diagnostic codes are typically applied at the end of or after the encounter.[14,17,23,24]

261 More recent machine-learning models for OUD and overdose risk report strong retrospective
262 discrimination, but most remain decoupled from real-time, clinical workflow, with limited
263 attention to calibration, latency, or operational usability.[18] In contrast, our strategy paired a high-
264 specificity silver standard for model development with DSM-5–aligned gold-standard
265 adjudication for prospective evaluation. This approach reduced label noise by limiting
266 misclassified or ambiguous cases in the training data, while quantifying real-world performance.
267 Unlike diagnostic code-only phenotypes, we used count-based longitudinal features (diagnoses,
268 medications, laboratory positives) to preserve burden and utilization signal, which may explain
269 the higher discrimination observed. Finally, few prior studies report fairness or drift monitoring
270 plans;[14,17] we explicitly outline future equity audits and recalibration, which are essential for
271 sustained, trustworthy deployment in dynamic ED environments.

272 Our findings demonstrate that an electronic phenotype can reliably identify patients with OUD in
273 the ED in real time, offering a practical bridge between predictive modeling and actionable
274 clinical use. Such integration has immediate implications for both research and care delivery: it
275 can streamline enrollment in clinical trials such as the ADAPT Trial,[13] reducing manual
276 screening burden and ensuring that eligible patients are recognized and offered evidence-based
277 treatments like buprenorphine. Beyond trial operations, real-time OUD detection can facilitate
278 more consistent linkage to addiction medicine and recovery resources, reducing variability across
279 clinicians and encounters. As health systems expand the use of phenotyping pipelines, this
280 approach could serve as a generalizable model for identifying other high-risk conditions
281 requiring timely intervention in the ED and beyond.

282 This study has several limitations. First, it was conducted within a single academic health system

using a single EHR vendor product and locally harmonized data; results may not generalize to other institutions, vendors, or patient populations. Second, the retrospective "silver-standard" label, based on high counts of OUD-related ICD codes, may misclassify patients due to documentation or utilization bias. Third, the prospective validation used stratified sampling based on model predictions rather than natural prevalence, so we were not able to directly report sensitivity and specificity, limiting external validity of performance values. Fourth, the model relied on structured EHR data, omitting the potentially-informative narrative content of clinical notes, and used simple imputation method (mode) that may introduce bias by over representing common values and obscuring true variability across patients or sites; undersampling and within-system validation may also overestimate performance. Finally, although demographic variables were excluded from modeling, bias may persist through proxy features.

Future work should focus on evaluating the clinical and operational impact of real-time OUD phenotyping in prospective, multi-site trials. Specifically, studies should assess whether automated identification improves rates of ED-initiated buprenorphine, treatment linkage, and long-term recovery outcomes. Ongoing monitoring for performance drift, calibration decay, and subgroup disparities will be critical to maintaining accuracy and fairness over time. Finally, extending this framework to other conditions, such as alcohol use disorder, suicidality, or sepsis in the ED (or beyond) could demonstrate the broader potential of embedded phenotyping to enhance real-time clinical decision support.

Materials and Methods

Study Design and Study Population

304 This multi-phase study involved two components: 1) a retrospective observational study utilizing
305 ED visit data from 2014 to 2025 to develop a predictive model, and 2) a prospective validation of
306 the resulting model. The validated model was created with the goal of integration into a clinical
307 decision support tool designed to identify OUD patients eligible for buprenorphine initiation in
308 the prospective ADAPT clinical trial.[13] This manuscript describes model development and
309 prospective phenotype validation in preparation for the ADAPT trial; results of the trial itself
310 will be reported after trial completion.
311
312 The model was trained on patient data from across the regional health system, including nine
313 EDs. The study population for this phase included all adult patients aged 18 and older who had
314 not opted out of research use. This study employed the STROBE reporting guidelines for
315 observational research.[25] All data processing, feature engineering, and model development were
316 performed using PySpark (*PySpark v3.2.1*) on our health system's local cloud-based secure
317 computing platform. The descriptive statistics of the study population, including the overall
318 cohort, the train/test subsets (after balancing and splitting), are summarized in **Table 1**.
319 Phenotype development was deemed exempt from human subject review by our institution's
320 IRB (protocol # 2000037541), and prospective use in the ADAPT clinical trial was approved
321 (protocol # 2000038624) with a waiver of informed consent. The ADAPT clinical trial is
322 registered on clinicaltrials.gov (ID: NCT06799117).
323
324
325 *Data Source, Variables, and Measurements*
326 All patient data were extracted from the health system's Epic EHR (Epic, Verona, WI) data
327 systems (Clarity and Caboodle, **Figure 4**, pipeline diagram). Using established extract–

transform–load (ETL) procedures, records were ingested into the local Computational Health Platform (CHP) and harmonized to the OMOP common data model for analysis. Routine data quality checks (completeness, conformance, and plausibility) were applied at each stage of the pipeline. Demographic information, including age, gender, race, and ethnicity, was collected but not included as model features. Past medical history items were categorized according to Agency for Healthcare Research and Quality (AHRQ) Clinical Classification Software (CSS) categories,[26] along with an additional variable that counted instances of OUD based on the provided ICD code value set (**Appendix 2**).[27] Medication exposures and orders were summarized as counts rather than simple presence/absence, and for pre-specified laboratory tests, we recorded the number of positive results. All feature tables were joined on the unique patient identifier. Then, variable names were normalized (lowercase; special characters removed), and missing values were imputed using the variable-wise mode. This count-based representation was selected because it preserves longitudinal burden and utilization signal compared with binary indicators.

Figure 4. System Architecture and Data Flow: This pipeline diagram illustrates the multi-phase process of data abstraction, model development, and deployment of a pre-trained OUD prediction model. It displays how the model was integrated into the EHR system to support real-time CDS for the timely identification of eligible ED patients. Chronicles is Epic's foundational operational database that stores real-time patient-level clinical data. Clarity is a relational reporting database that extracts and standardizes data from Chronicles for analytical use. Carboodle is an analytics-ready data warehouse built on top of both Chronicles and Clarity, designed to support research and operational reporting. The local cloud-based secure computing platform serves as the environment where the model is built, validated, and operated, using the OMOP common data model, which is a Common Data Model that YNHH database engineers extract from the Epic Caboodle database according to OHDSI specifications. Apache NiFi, deployed via Docker, facilitates automated and reproducible data ingestion and transformation workflows across systems. Within Epic, Datalink was utilized to enable targeted queries and cohort selection directly from the EHR.

353 **Silver Standard.** Since OUD prevalence in our ED cohort is low and manual physician
354 adjudication is resource-intensive, we trained the model using a silver-standard proxy rather than
355 a physician-adjudicated gold standard. The silver-standard outcome was defined from
356 longitudinal EHR data as the cumulative count of OUD-related ICD codes (value set in
357 **Appendix 2**) recorded in each patient's medical record. Patients with >250 cumulative OUD
358 codes were labeled positive for OUD. This high threshold was selected to avoid false positives
359 from high-frequency copy-and-paste documentation habits as well as diagnosis codes existing in
360 multiple places in the chart (such as problem list, past medical history, and encounter diagnoses),
361 resulting in a bloated number of diagnosis codes and refined through targeted clinical chart
362 reviews to prioritize specificity and maximize positive predictive value (PPV)[28], while also
363 optimizing sensitivity (**Appendix 3**). For downstream flagging, we created a composite
364 operational label to improve sensitivity: a patient was considered positive if either (i) the model
365 predicted OUD or (ii) the cumulative OUD ICD count was ≥25. This rule preserved the high-
366 specificity anchor used for training while broadening capture to patients with substantial—but
367 less extreme—documentation density.
368
369 **Gold Standard.** We used physician chart review consistent with the Diagnostic and Statistical
370 Manual of Mental Disorders, Fifth Edition (DSM-5) definition of OUD as our gold standard,[29]
371 with full methods detailed provided in **Appendix 4**.
372
373 **Model Development and Validation**
374 *Phenotyping Prediction Algorithm*

375 A random forest classifier was utilized to predict patient OUD status at the start of an ED
376 encounter based on the silver standard definition (XGBoost was not available in our PySpark,
377 secure compute environment; we also evaluated logistic regression (with and without
378 L1/LASSO)), but Random Forest delivered higher AUROC/PR-AUC and comparable calibration
379 on cross-validation, so it was selected as the primary model). Tree-based models are well known
380 for their strong generalization performance, high predictive accuracy, and interpretability.[30] To
381 address the imbalance in the dataset, we applied undersampling to the majority class (non-OUD)
382 through random sampling based on sliver standard defined outcomes, thereby aligning its
383 frequency with that of the positive class (OUD), and achieved a 10:1 ratio. Subsequently, we
384 performed feature engineering using PySpark's VectorAssembler to consolidate relevant features
385 into a single vector column. The balanced dataset was then divided into training and testing
386 subsets, with an 80:20 ratio, consistent with standard practice in model development. The
387 Random Forest classifier was trained on the training data, with hyperparameters optimized using
388 a Binary Classification Evaluator. [31,32] This evaluator assessed model performance based on the
389 area under the ROC curve (AUC), and 2-fold cross-validation was performed to mitigate the risk
390 of overfitting.
391
392 *Evaluation Analysis*
393 Phase 1 Silver Standard Evaluation
394 Model performance compared to the silver standard was evaluated using confusion matrices (i.e.,
395 2×2 contingency tables, **Figure 1a**), along with additional metrics including sensitivity (recall),
396 specificity, PPV (precision, the proportion of predicted positives that were true positives),
397 negative predictive value (NPV), false positive rate (FPR), false negative rate (FNR), accuracy,

398 and F1 score (harmonic mean of precision and recall, **Table 2**). The ROC AUC and the area
399 under the precision-recall curve (PR AUC) were also calculated and plotted (**Figure 1b, c**). In
400 addition, a calibration curve (**Figure 1d**) was plotted to assess the model's goodness of fit.
401 Feature importance was also generated and plotted to better understand the association between
402 features and the outcome variable.
403
404 Phase 2 Gold Standard Evaluation: Chart Review
405 To prospectively evaluate model performance, four resident physicians (SF, JM, CRK, OR) with
406 extensive experience caring for OUD patients conducted manual chart review of randomly-
407 selected cases. We selected cases based on model classification to address class imbalance
408 (patients classified as not having OUD far outnumbered those classified as having OUD),
409 randomly selecting 110 patients from each prediction class (OUD positive or negative by model
410 prediction), with the goal of retaining at least 100 patients in each class and a total of 200
411 patients after exclusions. Sampling was restricted to a single visit per patient. To ensure
412 consistency with the Epic CDS alert algorithm logic and the inclusion criteria used in prior
413 phases, we applied exclusion criteria to remove cases involving pregnant patients or patients
414 under 18 years of age.
415
416 Each case was reviewed by two resident physicians, who were given a medical record number
417 and date of encounter (the date at which the model prediction was made) and asked to determine
418 whether the patient met criteria for a diagnosis of OUD according to the DSM-5 definition at the
419 start of the encounter; reviewers were blinded to the model's predictions. To ensure consistency
420 and accuracy in labeling, reviewers followed structured chart review guidance, adapted from

421 Pulumbo et al.,[33] as detailed in **Appendix 4**. In addition to structured data elements, reviewers
422 were directed to review unstructured clinical notes, which could contain data and details not
423 included in predictive model features, all of which were based on structured data elements. If
424 reviewers noted that they had cared for a patient whose chart they were reviewing, the patient
425 was excluded to avoid bias related to personal clinical experience.
426
427 Reviewers' assessments of each patient's OUD status were compared, and inter-reviewer
428 agreement was assessed with Cohen's kappa statistic. In cases in which both reviewers agreed on
429 the patient's OUD status, their assessment was considered the gold standard. In cases of
430 disagreement, two attending physicians (EM and MI) with expertise in OUD reviewed the cases
431 independently; if they both agreed, their assessment was considered the gold standard. If they
432 disagreed, they discussed the case to reach a final consensus gold standard diagnosis.

433 Model performance with respect to the gold standard was reported as positive predictive value
434 (PPV, the proportion of phenotype-positive cases that met gold standard criteria for OUD) and
435 negative predictive value (NPV, the proportion of phenotype-negative cases that did not meet
436 gold standard criteria for OUD). These metrics were chosen to directly assess the clinical
437 relevance of the phenotype in identifying true positive and negative cases of OUD, particularly
438 in the context of DSM-5 criteria.[17]

439 **Real-time Implementation**

440 In our real-time implementation of this machine-learning OUD phenotype, on a nightly (~24-
441 hour) schedule, encounters and longitudinal EHR elements were extracted from Epic
442 Clarity/Caboodle into the institutional Computational Health Platform (CHP) and harmonized to

443 the OMOP common data model. The trained OUD phenotype model was then executed as a
444 daily batch job across the OMOP tables to produce a patient-level phenotype probability and
445 binary flag for all eligible patients. Flags were published back to Epic via Apache NiFi and Epic
446 DataLink as CSV payloads to a monitored drop location and ingested into production, yielding
447 ≤24-hour latency between documentation and flag availability (**Figure 4**).
448
449 At ED arrival/registration, the real-time phenotype rules implemented in the Epic EHR
450 consumed the latest model flag and applied additional clinical logic. Adults (≥18 years) triggered
451 an alert if they either met the model's operating threshold (selected during validation to balance
452 PPV and sensitivity) or presented with OUD-relevant chief complaints, received pre-hospital
453 naloxone, or had triage documentation of a clinical opiate withdrawal scale (COWS) score > 7.
454 Alerts were suppressed for patients with an existing prescription in the predefined medication
455 grouping (given the trial's goal to initiate medication treatment for OUD, **Appendix 5**),
456 pregnancy, or documented research opt-out.
457
458
459

Acknowledgment

We acknowledge the use of ChatGPT (OpenAI, GPT-5.0) and Yale's Clarity GPT4 for facilitating advanced language modeling and Grammarly for enhancing our manuscript's clarity and quality.

464 **Reference**

465 1. Website. Tanz LJ, Gladden RM, Dinwiddie AT, et al. Routes of Drug Use Among Drug
466 Overdose Deaths — United States, 2020–2022. MMWR Morb Mortal Wkly Rep
467 2024;73:124–130. DOI: http://dx.doi.org/10.15585/mmwr.mm7306a2

468 2. Boté SH. U.S. opioid epidemic: Impact on public health and review of Prescription Drug
469 Monitoring Programs (PDMPs). *Online J Public Health Inform*. 2019;11(2):e18.

470 3. Pickens CM, Hoots BE, Casillas SM, Scholl L. Prevalences of and characteristics associated
471 with single- and polydrug-involved U.S. Emergency Department Visits in 2018. *Addict*
472 *Behav*. 2022;125:107158.

473 4. Moghtaderi A, Zocchi MS, Pines JM, Venkat A, Black B. Estimating the uncertain effect of
474 the COVID pandemic on drug overdoses. *PLoS One*. 2023;18(8):e0281227.

475 5. Wakeman SE, Larochelle MR, Ameli O. Comparative Effectiveness of Different Treatment
476 Pathways for Opioid Use Disorder [published correction appears in JAMA Netw Open.
477 *JAMA Netw Open*. 2020;7(5). doi:10.1001/jamanetworkopen.2024.19798

478 6. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated
479 buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
480 *JAMA*. 2015;313(16):1636-1644.

481 7. Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency
482 department with buprenorphine. *Ann Emerg Med.* 2019;73(5):481-487.

483 8. Hawk K, Hoppe J, Ketcham E, et al. Consensus recommendations on the treatment of
484 opioid use disorder in the emergency department. *Ann Emerg Med.* 2021;78(3):434-442.

485 9. Chhabra N, Smith D, Dickinson G, et al. Trends and disparities in initiation of
486 buprenorphine in US emergency departments, 2013-2022. *JAMA Netw Open*.
487 2024;7(9):e2435603.

488 10. Cao SS, Dunham SI, Simpson SA. Prescribing buprenorphine for opioid use disorders in the
489 ED: A review of best practices, barriers, and future directions. *Open Access Emerg Med*.
490 2020;12:261-274.

491 11. Hawk KF, D'Onofrio G, Chawarski MC, et al. Barriers and facilitators to clinician
492 readiness to provide emergency department-initiated buprenorphine. *JAMA Netw Open*.
493 2020;3(5):e204561.

494 12. Melnick ER, Nath B, Dziura JD, et al. User centered clinical decision support to implement
495 initiation of buprenorphine for opioid use disorder in the emergency department: EMBED
496 pragmatic cluster randomized controlled trial. *BMJ*. 2022;377:e069271.

497 13. Iscoe MS, Diniz Hooper C, Levy DR, et al. Adaptive decision support for addiction
498 treatment to implement initiation of buprenorphine for opioid use disorder in the emergency
499 department: protocol for the ADAPT Multiphase Optimization Strategy trial. *BMJ Open*.
500 2025;15(2):e098072.

501 14. Ranapurwala SI, Alam IZ, Pence BW, et al. Development and validation of an electronic
502 health records-based opioid use disorder algorithm by expert clinical adjudication among

503 patients with prescribed opioids. *Pharmacoepidemiol Drug Saf*. 2023;32(5):577-585.

504 15. Eguale T, Bastardot F, Song W, et al. A machine learning application to classify patients at
505 differing levels of risk of opioid use disorder: Clinician-based validation study. *JMIR Med*
506 *Inform*. 2024;12:e53625.

507 16. Lo-Ciganic WH, Huang JL, Zhang HH, et al. Evaluation of machine-learning algorithms for
508 predicting opioid overdose risk among Medicare beneficiaries with opioid prescriptions.
509 *JAMA Netw Open*. 2019;2(3):e190968.

510 17. Chartash D, Paek H, Dziura JD, et al. Identifying opioid use disorder in the emergency
511 department: Multi-system electronic health record-based computable phenotype derivation
512 and validation study. *JMIR Med Inform*. 2019;7(4):e15794.

513 18. Taylor RA, Gilson A, Schulz W, et al. Computational phenotypes for patients with opioid-
514 related disorders presenting to the emergency department. *PLoS One*. 2023;18(9):e0291572.

515 19. Banks TJ, Nguyen TD, Uhlmann JK, Nair SS, Scherrer JF. Predicting opioid use disorder
516 before and after the opioid prescribing peak in the United States: A machine learning tool
517 using electronic healthcare records. *Health Informatics J*. 2023;29(2):14604582231168826.

518 20. Song SL, Dandapani HG, Estrada RS, Jones NW, Samuels EA, Ranney ML. Predictive
519 Models to Assess Risk of Persistent Opioid Use, Opioid Use Disorder, and Overdose. *J*
520 *Addict Med*. 2024;18(3):218-239.

521 21. Poulsen MN, Freda PJ, Troiani V, Davoudi A, Mowery DL. Classifying Characteristics of
522 Opioid Use Disorder From Hospital Discharge Summaries Using Natural Language

523 Processing. *Front Public Health*. 2022;10:850619.

524 22. Mccamic E. June 27, 2022: EMBED Publishes Results From Study of Buprenorphine
525 Initiation in Emergency Departments. Rethinking Clinical Trials. June 27, 2022. Accessed
526 October 8, 2025. https://rethinkingclinicaltrials.org/news/june-27-2022-embed-trial-did-not-
527 increase-rate-of-emergency-buprenorphine-initiation-for-opioid-use-disorder-increased-
528 number-of-physicians-using-the-lifesaving-practice/

529 23. Poulsen MN, Nordberg CM, Troiani V, Berrettini W, Asdell PB, Schwartz BS.
530 Identification of opioid use disorder using electronic health records: Beyond diagnostic
531 codes. *Drug Alcohol Depend*. 2023;251:110950.

532 24. Venkatesh A, Malicki C, Hawk K, D'Onofrio G, Kinsman J, Taylor A. Assessing the
533 readiness of digital data infrastructure for opioid use disorder research. *Addict Sci Clin*
534 *Pract*. 2020;15(1):24.

535 25. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
536 Statement: guidelines for reporting observational studies. Accessed October 8, 2025.
537 https://www.equator-network.org/reporting-guidelines/strobe/

538 26. Clinical Classifications Software (CCS) for ICD-9-CM. Accessed September 11, 2025.
539 https://hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp

540 27. Website. https://www.acep.org/cedr/measures

541 28. Holmgren AJ, Downing NL, Bates DW, et al. Assessment of Electronic Health Record Use
542 Between US and Non-US Health Systems. *JAMA Intern Med*. 2021;181(2):251-259.

543 29. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*.;
544 2022.

545 30. Sullivan W. *Decision Tree and Random Forest: Machine Learning and Algorithms: The*
546 *Future Is Here!* Createspace Independent Publishing Platform; 2018.

547 31. Ayan D. Evaluating Binary Classification Models with PySpark. Medium. February 4,
548 2024. Accessed July 7, 2025. https://medium.com/@demrahayan/evaluating-binary-
549 classification-models-with-pyspark-2afc5ac7937f

550 32. BinaryClassificationEvaluator — PySpark 4.0.0 documentation. Accessed July 7, 2025.
551 https://spark.apache.org/docs/latest/api/python/reference/api/pyspark.ml.evaluation.BinaryC
552 lassificationEvaluator.html

553 33. Palumbo SA, Adamson KM, Krishnamurthy S, et al. Assessment of Probable Opioid Use
554 Disorder Using Electronic Health Record Documentation. *JAMA Netw Open*.
555 2020;3(9):e2015909.


a)
Confusion Matrix
Negative
Positive
True label
3855
12
171
208
Negative
Positive
Predicted label
3500
3000
2500
2000
1500
1000
500
b)
ROC Curve
True Positive Rate
False Positive Rate
ROC curve (AUC = 0.99)
c)
Precision-Recall Curve
PR curve (AUC = 0.92)
Precision
Recall
d)
Calibration Curve
Fraction of Positives
Mean Predicted Probability

Figure_1


Feature Importance
Stimulant related disorders
Mental and substance use disorders in remission
Agents for opioid withdrawal opioid type
Other specified substance related disorders
Methadone presence in urine by screen method
Central alpha 2 receptor agonists
Antianxiety agent antihistamine type
Smoking deterrents nicotine type
Trauma and stressor related disorders
Opiates presence in urine by screen method
Psychological and psychiatric evaluation and therapy
Diagnostic biologicals
Sedative related disorders
Vitamins B1 thiamine and derivatives
Cannabis related disorders
Depressive disorders
Alcohol related disorders
Opioid reversal agents opioid antagonists
Hepatitis
Poisoning by drugs initial encounter
Benzodiazepines presence in urine by screen method
Analgesic opioid agonists
Antidepressant serotonin 2 antagonist reuptake inhibitors saris
NSAID analgesics cox non specific propionic acid derivatives
Antianxiety agent benzodiazepines
Variables
0.00
0.01
0.02
0.03
0.04
0.05
0.06
Importance score
Category
PMH
Medication
Labs
Procedures

Figure_2



Figure_3


Input <<<
Phenotype Registry Data
Chronicles
Unstructured/No-SQL Data
ETL
Phenotype Registry Data
Clarity
Structured/SQL Data
OUD Registry Phenotype SQL Rules
ETL
Phenotype Registry Data
Caboodle
>>> Output
Datalink process picks up csv and imports into Epic
Apache NiFi Delivers csv of patient flags to droppff folder
Daily run of model generates patient flags
OUD Machine Learning Phenotype Label
Movelt picks up csv and delivers to EPIC-facing folder
Local Cloud Based Secure Computing Platform
- Registry Data
- Access Log Data
OUD Machine Learning Model Train
Custom ETL Registry Data
OMOP Image Data
Data updates every 24 hours

Figure_4